Liquid biopsy stands as a groundbreaking advancement in cancer research, offering a non-invasive method to detect and monitor cancer through analyzing biomarkers present in bodily fluids like blood or urine. Unlike traditional tissue biopsies, which can be invasive and sometimes impractical for frequent monitoring, liquid biopsy provides a less burdensome alternative. By detecting circulating tumor cells, cell-free DNA, and other molecules shed by tumors into the bloodstream, liquid biopsy enables early detection of cancer, monitoring treatment response, and detecting recurrence with greater precision. Its potential extends beyond diagnosis, allowing for personalized treatment strategies based on the tumor's genetic profile. As research continues to refine and expand the utility of liquid biopsy, it holds promise for revolutionizing cancer management by offering a minimally invasive yet powerful tool in the fight against this complex disease.



Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Nanomedicine in over 45,000 patients and no cancer
Thomas Jay Webster, Brown University, United States